On Aug. 23, COMPASS pathways, a life science firm, finally got the thumbs up from the Food and Drug Administration to conduct clinical trials to treat patients who did not have luck with the other conventional treatments for depression.
Around 216 patients will partake in this trial in Europe and in North America starting in early September. The clinical study will actually need a smaller amount of patients and reduce treatment time up to an hour and a half.
Most physicians recommend treatments that do not necessarily work for some patients. This will give them a positive reinforcement that they will finally get the healthy help they have been longing. NOBODY wishes to feel as if they’ve been lobotomized from the prescribed medication that a physician has given you.
Since the early 60’s, the FDA has been apprehensive about the treatment of psilocybin due to its history of people in the past using it recreationally to experience these hallucinogenic trips.
Its mass hysteria caused it to be such a taboo subject in which any affiliation with these “magic mushrooms” is said to be thought-out as crazy or straight out rejected by any physician.
Previous research and studies show proof that a small dose of this agent can immediately assist the reduction of depression and other conditions such as drug addicts trying to become sober, terminally ill patients who suffer from anxiety because of thought of them dying and past ex-military veterans who experience PTSD.
Read the full article at Talon Marks